Dacarbazine

Generic Name
Dacarbazine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C6H10N6O
CAS Number
4342-03-4
Unique Ingredient Identifier
7GR28W0FJI
Background

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Indication

For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.

Associated Conditions
Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Associated Therapies
-
Clinical Trials
Related News

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Phase 1
Completed
Conditions
Leiomyosarcoma
Interventions
Drug: Unesbulin
Drug: Dacarbazine
First Posted Date
2018-12-03
Last Posted Date
2024-03-15
Lead Sponsor
PTC Therapeutics
Target Recruit Count
41
Registration Number
NCT03761095
Locations
🇺🇸

John Hopkins, Baltimore, Maryland, United States

🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

🇺🇸

Washington University Medical Campus, Saint Louis, Missouri, United States

and more 1 locations

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

First Posted Date
2018-11-28
Last Posted Date
2024-04-04
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
250
Registration Number
NCT03755804
Locations
🇺🇸

Maine Children's Cancer Program, Scarborough, Maine, United States

🇺🇸

St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

First Posted Date
2018-10-19
Last Posted Date
2024-11-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
155
Registration Number
NCT03712202
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

and more 14 locations

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

First Posted Date
2018-08-24
Last Posted Date
2024-11-05
Lead Sponsor
Seagen Inc.
Target Recruit Count
255
Registration Number
NCT03646123
Locations
🇺🇸

Texas Oncology - Flower Mound, Flower Mound, Texas, United States

🇺🇸

Clinical Research Alliance - Abraham Mittelman, MD, LLC, Purchase, New York, United States

🇨🇿

Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Other, Czechia

and more 73 locations

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

First Posted Date
2018-05-17
Last Posted Date
2019-11-18
Lead Sponsor
King Abdullah International Medical Research Center
Target Recruit Count
220
Registration Number
NCT03527628
Locations
🇸🇦

King Abdulaziz Medical City, Ministry of National Guard, Riyadh, Saudi Arabia

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

First Posted Date
2018-05-07
Last Posted Date
2023-11-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
150
Registration Number
NCT03517137
Locations
🇳🇱

Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands

🇳🇱

Erasmus MC, Rotterdam, Netherlands

🇵🇱

Maria Sklodowska Curie National Institute of Oncology - National Research Institute, Warsaw, Poland

and more 13 locations

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

First Posted Date
2018-01-23
Last Posted Date
2024-11-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
340
Registration Number
NCT03407144
Locations
🇺🇸

University of Chicago ( Site 0066), Chicago, Illinois, United States

🇺🇸

Cohen Children's Medical Center of New York ( Site 0052), New Hyde Park, New York, United States

🇺🇸

Columbia University/Herbert Irving Cancer Center ( Site 0063), New York, New York, United States

and more 90 locations

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

First Posted Date
2017-11-06
Last Posted Date
2023-12-26
Lead Sponsor
University of Washington
Target Recruit Count
50
Registration Number
NCT03331341
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

First Posted Date
2017-09-11
Last Posted Date
2024-08-13
Lead Sponsor
Grupo Espanol de Investigacion en Sarcomas
Target Recruit Count
197
Registration Number
NCT03277924
Locations
🇮🇹

Istituto Nazionale dei Tumori, Milano, Italy

🇪🇸

Hospital Universitario Virgen del Rocío, Sevilla, Spain

🇪🇸

Hospital Universitari i Politècnic La Fe, Valencia, Spain

and more 10 locations

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

First Posted Date
2017-07-28
Last Posted Date
2023-09-15
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
82
Registration Number
NCT03233347
Locations
🇺🇸

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy